Cargando…

Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma

Autologous stem cell transplant (ASCT) is the standard of care in transplant-eligible multiple myeloma patients and is associated with significant improvement in progression-free survival (PFS), complete remission rates (CR), and overall survival (OS). However, majority of patients eventually relaps...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Mansour, Zeina, Ramanathan, Muthalagu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265378/ https://www.ncbi.nlm.nih.gov/pubmed/25525435 http://dx.doi.org/10.1155/2014/652395

Ejemplares similares

Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2022)

A Case of Multiple Myeloma in a 17-Year-Old Girl Treated with Autologous Hematopoietic Stem Cell Transplantation (ASCT)
por: Van Man, Huynh, et al.
Publicado: (2019)

Autologous stem cell transplant (ASCT) for AIDS-related lymphoma (ARL)
por: Krishnan, A, et al.
Publicado: (2009)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

Successful autologous stem cell transplantation (ASCT) in a patient with juvenile dermatomyositis
por: Holzer, U, et al.
Publicado: (2008)

Interaction between IL-6 and TNF-α genotypes associated with bacteremia in multiple myeloma patients submitted to autologous stem cell transplantation (ASCT)
por: Trigo, Fernanda M.B., et al.
Publicado: (2014)

Current status of autologous stem cell transplantation for multiple myeloma
por: Al Hamed, Rama, et al.
Publicado: (2019)

The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial
por: Striha, Alina, et al.
Publicado: (2018)

Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
por: Bird, Sarah A., et al.
Publicado: (2020)

Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation
por: Al-Anazi, Khalid Ahmed
Publicado: (2012)

Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study
por: Salmasinia, Donya, et al.
Publicado: (2010)

Feasibility and benefits of a structured prehabilitation programme prior to autologous stem cell transplantation (ASCT) in patients with myeloma; a prospective feasibility study
por: Mawson, Susan, et al.
Publicado: (2021)

Update on the Role of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Tosi, P., et al.
Publicado: (2012)

Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial
por: Gimsing, P, et al.
Publicado: (2015)

Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia
por: Abdrabou, Ahmed Kotb, et al.
Publicado: (2021)

Ethical issues in autologous stem cell transplantation (ASCT) in advanced breast cancer: A systematic literature review
por: Droste, Sigrid, et al.
Publicado: (2011)

COVID 19 Infection in Autologous Stem Cell Transplant (ASCT) Recipients: a Single Institution Observational Cohort
por: Moreb, Jan S., et al.
Publicado: (2023)

Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Tuchman, S. A., et al.
Publicado: (2012)

Autologous Stem Cell Transplantation in Multiple Myeloma with Renal Failure: Friend or Foe?
por: Zhong, Hongfei, et al.
Publicado: (2019)

Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
por: Nahi, Hareth, et al.
Publicado: (2022)

Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant
por: Thalambedu, Nishanth, et al.
Publicado: (2023)

Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant
por: Thalambedu, Nishanth, et al.
Publicado: (2022)

High dose therapy and autologous stem cell transplant in older adults with multiple myeloma
por: Wildes, Tanya M, et al.
Publicado: (2015)

PB1996: TREATMENT PATHWAYS AT FIRST RELAPSE POST-ASCT IN MULTIPLE MYELOMA: IMPACT OF MAINTENANCE THERAPY ON TREATMENT OPTIONS
por: Duane, C., et al.
Publicado: (2022)

Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma: Past, Present, and Future
por: Ozaki, Shuji, et al.
Publicado: (2014)

Complete response after autologous stem cell transplant in multiple myeloma
por: Kumar, Lalit, et al.
Publicado: (2014)

Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma
por: Paquin, Ashley, et al.
Publicado: (2020)

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
por: Yarlagadda, Lakshmi, et al.
Publicado: (2021)

Interrupted Identities: Autologous Stem Cell Transplant in Patients With Multiple Myeloma
por: Halpin, Sean N, et al.
Publicado: (2021)

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
por: Srour, Samer A., et al.
Publicado: (2021)

Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma
por: Bergantim, Rui, et al.
Publicado: (2012)

Sequential, Autologous Hematopoietic Stem Cell Transplant Followed by Renal Transplant in Multiple Myeloma
por: Bhowmik, D., et al.
Publicado: (2017)

Treatment of multiple myeloma based on autologous stem cell transplant: An overview of systematic reviews
por: Liang, Juan, et al.
Publicado: (2023)

Review on Haploidentical Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies
por: Fabricius, William A., et al.
Publicado: (2016)

Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients
por: FU, CHENGCHENG, et al.
Publicado: (2013)

Comparison of single and double autologous stem cell transplantation in multiple myeloma patients
por: Malkan, Umit Yavuz, et al.
Publicado: (2021)

Long-Term Responders After Autologous Stem Cell Transplantation in Multiple Myeloma
por: Oliver-Caldes, Aina, et al.
Publicado: (2022)

Experience of Autologous Stem Cell Transplant in Multiple Myeloma: The Patient and Caregiver Perspective
por: Hansen, Doris K, et al.
Publicado: (2023)

PB1992: HISPANIC ETHNICITY AS A STRONG PREDICTOR OF POOR RESPONSE TO INDUCTION THERAPY AND ASCT IN TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
por: Chineke, I., et al.
Publicado: (2022)

Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?
por: Morè, Sonia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_knvf35hr8fel5f3tpcs4ffm686